CClinicalTrials.gg
CompletedNCT03224533Updated Jul 21, 2017

Walnut Consumption and Diabetes Risk

An observational study in Diabetes Mellitus, sponsored by University of California, Los Angeles. Completed at 1 site in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-07-21.

Sponsored by University of California, Los Angeles · Observational

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
34,121
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Multiple NHANES surveys were combined and weighted to evaluate relationships between walnut consumption and type 2 diabetes mellitus using various independent measures of diabetes status and risk. After risks were ascertained, interactions with gender were analyzed.

Read the detailed description

Background. Dietary interventions and cohort studies of tree nuts lowering glucose levels for diabetes suggest a possible effect with walnuts. Objective. To examine the associations between walnut consumption and diabetes risk through data from the National Health and Nutrition Examination Survey (NHANES). Methods. NHANES survey data for 1999 through 2014 was pooled for adults with 24 hour recall dietary data. Risk of diabetes was based on self-report, medication use, fasting plasma glucose levels, and hemoglobin A1c (HbA1c) levels. Individuals were characterized as reporting consumption of walnuts, mixed 'nuts', or no nuts.

02

Conditions studied

  • Diabetes Mellitus

Browse trials for

Keywords

  • nut consumption
  • NHANES
  • epidemiology
  • plasma glucose
  • hemoglobin A1c
03

In context

Diabetes Mellitus

10,923 studies on the registry are indexed under Diabetes Mellitus; 1,318 are open to participants now.

This study's enrollment of 34,121 is above the median of 233 across 2,218 observational studies indexed under Diabetes Mellitus.

Browse Diabetes Mellitus studies →

Lead sponsor

University of California, Los Angeles is the lead sponsor of 1,142 studies on the registry; 192 are open to participants now.

Of its 91 completed or terminated interventional studies of FDA-regulated products, 66 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

The National Health and Nutrition Examination Survey (NHANES) is a cross-sectional, probability survey administered to the US civilian population aged from 0 to 85 years. This study used continuous NHANES data collected from 1999 to 2014, covering eight cycles of data collection (N=82,091). Participants were excluded from analysis for being under 18 (N=34,735) and not having data on either day of the 24-hour food intake (N=6,533). In an attempt to have a control group free of nut consumers, individuals who consumed peanuts, but not other nuts on the day of recall, were excluded from the analysis (N=6,702). After exclusions, our analytic sample N was 34,121, representing a population size of approximately 176 million individuals.

Inclusion criteria

  • NHANES data from 1999-2014 with food recalls and dietary food intake

Exclusion criteria

Exclusion Criteria:

  • not having data on either day of the 24-hour food intake
  • individuals who consumed peanuts, but not other nuts on the day of recall, were excluded from the analysis
05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
34,121 participants (actual)
Patient registry
No

Groups and cohorts

  • No Nuts

    All other foods that did not include walnuts or other nuts were classified as "no nuts" (NN).

    Diagnostic Test: Diabetes Outcome

  • Other Nuts

    Foods codes describing nuts that are not walnuts (i.e. cashew nuts, pistachios, etc.) or nut-containing foods that do not commonly contain walnuts (e.g. granola) were classified as "other nuts" (ON).

    Diagnostic Test: Diabetes Outcome

  • Walnuts with other nuts

    food codes describing nut mixes and foods that commonly include walnuts were classified as "walnuts with other nuts" (WwON)

    Diagnostic Test: Diabetes Outcome

  • Walnuts with high certainty

    Foods consisting entirely or mostly of walnuts were classified as "walnuts with high certainty" (WwHC)

    Diagnostic Test: Diabetes Outcome

Interventions

  • Diagnostic testDiabetes Outcome

    based on self report definition, fasting plasma glucose, and hemoglobin A1c

06

What researchers measure

Primary outcomes

  1. Diabetes Outcome- self report

    Based on self-report as told by a doctor

    Time frame: 1999-2014

  2. Diabetes Outcome- Fasting Plasma Glucose

    Based on FPG levels

    Time frame: 1999-2014

  3. Diabetes Outcome- Hemoglobin A1c

    Based on HbA1c levels

    Time frame: 1999-2014

  4. Diabetes Outcome- Combined Definition

    Based on both FPG and HbA1c levels

    Time frame: 1999-2014

Secondary outcomes

  1. Sex Interaction

    based on the previously stated definition outcomes

    Time frame: 1999-2014

07

Study locations

1 site
  • University of California Los Angeles
    Los Angeles, California 90095, United States
08

References and documents

Publications

  • Brennan AM, Sweeney LL, Liu X, Mantzoros CS. Walnut consumption increases satiation but has no effect on insulin resistance or the metabolic profile over a 4-day period. Obesity (Silver Spring). 2010 Jun;18(6):1176-82. doi: 10.1038/oby.2009.409. Epub 2009 Nov 12. PubMed 19910942 ↗
  • Kalgaonkar S, Almario RU, Gurusinghe D, Garamendi EM, Buchan W, Kim K, Karakas SE. Differential effects of walnuts vs almonds on improving metabolic and endocrine parameters in PCOS. Eur J Clin Nutr. 2011 Mar;65(3):386-93. doi: 10.1038/ejcn.2010.266. Epub 2010 Dec 15. PubMed 21157477 ↗
  • Katz DL, Davidhi A, Ma Y, Kavak Y, Bifulco L, Njike VY. Effects of walnuts on endothelial function in overweight adults with visceral obesity: a randomized, controlled, crossover trial. J Am Coll Nutr. 2012 Dec;31(6):415-23. doi: 10.1080/07315724.2012.10720468. PubMed 23756586 ↗
  • Ma Y, Njike VY, Millet J, Dutta S, Doughty K, Treu JA, Katz DL. Effects of walnut consumption on endothelial function in type 2 diabetic subjects: a randomized controlled crossover trial. Diabetes Care. 2010 Feb;33(2):227-32. doi: 10.2337/dc09-1156. Epub 2009 Oct 30. PubMed 19880586 ↗
  • Mukuddem-Petersen J, Stonehouse Oosthuizen W, Jerling JC, Hanekom SM, White Z. Effects of a high walnut and high cashew nut diet on selected markers of the metabolic syndrome: a controlled feeding trial. Br J Nutr. 2007 Jun;97(6):1144-53. doi: 10.1017/S0007114507682944. Epub 2007 Mar 7. PubMed 17381974 ↗
  • Tapsell LC, Batterham MJ, Teuss G, Tan SY, Dalton S, Quick CJ, Gillen LJ, Charlton KE. Long-term effects of increased dietary polyunsaturated fat from walnuts on metabolic parameters in type II diabetes. Eur J Clin Nutr. 2009 Aug;63(8):1008-15. doi: 10.1038/ejcn.2009.19. Epub 2009 Apr 8. PubMed 19352378 ↗
  • Tapsell LC, Gillen LJ, Patch CS, Batterham M, Owen A, Bare M, Kennedy M. Including walnuts in a low-fat/modified-fat diet improves HDL cholesterol-to-total cholesterol ratios in patients with type 2 diabetes. Diabetes Care. 2004 Dec;27(12):2777-83. doi: 10.2337/diacare.27.12.2777. PubMed 15562184 ↗
  • Wu L, Piotrowski K, Rau T, Waldmann E, Broedl UC, Demmelmair H, Koletzko B, Stark RG, Nagel JM, Mantzoros CS, Parhofer KG. Walnut-enriched diet reduces fasting non-HDL-cholesterol and apolipoprotein B in healthy Caucasian subjects: a randomized controlled cross-over clinical trial. Metabolism. 2014 Mar;63(3):382-91. doi: 10.1016/j.metabol.2013.11.005. Epub 2013 Nov 12. PubMed 24360749 ↗
  • Moravej H, Salehi A, Razavi Z, Moein MR, Etemadfard H, Karami F, Ghahremani F. Chemical Composition and the Effect of Walnut Hydrosol on Glycemic Control of Patients With Type 1 Diabetes. Int J Endocrinol Metab. 2016 Jan 30;14(1):e34726. doi: 10.5812/ijem.34726. eCollection 2016 Jan. PubMed 27335580 ↗
  • Bullard KM, Ali MK, Imperatore G, Geiss LS, Saydah SH, Albu JB, Cowie CC, Sohler N, Albright A, Gregg EW. Receipt of Glucose Testing and Performance of Two US Diabetes Screening Guidelines, 2007-2012. PLoS One. 2015 Apr 30;10(4):e0125249. doi: 10.1371/journal.pone.0125249. eCollection 2015. PubMed 25928306 ↗
  • Guo K, Zhou Z, Jiang Y, Li W, Li Y. Meta-analysis of prospective studies on the effects of nut consumption on hypertension and type 2 diabetes mellitus. J Diabetes. 2015 Mar;7(2):202-12. doi: 10.1111/1753-0407.12173. Epub 2014 Jul 29. PubMed 24893671 ↗
  • Luo C, Zhang Y, Ding Y, Shan Z, Chen S, Yu M, Hu FB, Liu L. Nut consumption and risk of type 2 diabetes, cardiovascular disease, and all-cause mortality: a systematic review and meta-analysis. Am J Clin Nutr. 2014 Jul;100(1):256-69. doi: 10.3945/ajcn.113.076109. Epub 2014 May 21. PubMed 24847854 ↗
  • Zhou D, Yu H, He F, Reilly KH, Zhang J, Li S, Zhang T, Wang B, Ding Y, Xi B. Nut consumption in relation to cardiovascular disease risk and type 2 diabetes: a systematic review and meta-analysis of prospective studies. Am J Clin Nutr. 2014 Jul;100(1):270-7. doi: 10.3945/ajcn.113.079152. Epub 2014 May 7. PubMed 24808491 ↗
  • Pan A, Sun Q, Manson JE, Willett WC, Hu FB. Walnut consumption is associated with lower risk of type 2 diabetes in women. J Nutr. 2013 Apr;143(4):512-8. doi: 10.3945/jn.112.172171. Epub 2013 Feb 20. PubMed 23427333 ↗
  • Guo F, Moellering DR, Garvey WT. Use of HbA1c for diagnoses of diabetes and prediabetes: comparison with diagnoses based on fasting and 2-hr glucose values and effects of gender, race, and age. Metab Syndr Relat Disord. 2014 Jun;12(5):258-68. doi: 10.1089/met.2013.0128. Epub 2014 Feb 10. PubMed 24512556 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 21, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03224533
Lead sponsor
University of California, Los Angeles
Collaborators
California Walnut Commission
Responsible party
Lenore Arab, PhD (Principal Investigator, University of California, Los Angeles) — Principal investigator
First posted
Jul 21, 2017
Start date
Jun 1, 2015
Primary completion
May 30, 2017
Completion
May 30, 2017
Last update
Jul 21, 2017

Study contacts

Lenore Arab, MSc, PhD
principal investigator · David Geffen School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion